The histone‐lysine N‐methyltransferase enzyme EZH2 (enhancer of zeste homolog 2), which catalyzes the addition of methyl groups to histone H3 at lysine 27 thereby silencing gene function, plays an important role in glioma progression.[64, 65] EZH2 inhibitor GSK343 upregulates EZH2 target genes, leading to suppression of GBM growth and reversing PMT by controlling N‐cadherin and vimentin expression.[66] Vinchure et al. The gene discussed is CDH2; the disease is central nervous system cancer.